U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811324) titled 'Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Hispanic Adults' on Jan. 31.
Brief Summary: Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging Hispanic community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide in the Hispanic community has been on the rise since FDA approval was issued,...